New pre-clinical data shows that a low dose of a proprietary tetrahydrocannabinol (THC) drug candidate developed by Israel’s Therapix Biosciences significantly reversed age-related cognitive impairment in old mice.
Therapix focuses on the development of cannabinoid-based drugs. The candidate dubbed THX-ULD01 is intended for the treatment of mild cognitive impairment (MCI).
MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal age-related changes but are not severe enough to interfere with daily life or independent function.
The pre-clinical animal study was designed and conducted by Prof. Yosef Sarne of the Sackler Faculty of Medicine at Tel Aviv University.
“The data from this pre-clinical animal study suggest that extremely low doses of THC, which are devoid of any psychotropic effect and do not induce desensitization, could